Foghorn Therapeutics Inc (FHTX)

Apr 16, 2026

Strength seen in Dianthus Therapeutics, Inc. (DNTH): Can its 5.6% jump turn into more strength? - MSN

Apr 16, 2026

Apr 13, 2026

Foghorn (NASDAQ: FHTX) CEO shifts 213,410 shares in trust-to-trust gifts - Stock Titan

Apr 13, 2026

Apr 11, 2026

If You Invested $1,000 in Foghorn Therapeutics Inc. (FHTX) - Stock Titan

Apr 11, 2026

Apr 10, 2026

Trading Recap: Can Foghorn Therapeutics Inc weather a recession2026 Spike Watch & Technical Pattern Recognition Alerts - baoquankhu1.vn

Apr 10, 2026

Apr 09, 2026

Foghorn Therapeutics to Present New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting - Investing News Network

Apr 09, 2026

Apr 09, 2026

Foghorn to present preclinical cancer data at AACR meeting By Investing.com - Investing.com South Africa

Apr 09, 2026

Apr 09, 2026

Foghorn Therapeutics details preclinical advances across oncology programs - Traders Union

Apr 09, 2026

Apr 09, 2026

Foghorn to present preclinical cancer data at AACR meeting - Investing.com

Apr 09, 2026

Apr 09, 2026

Foghorn Therapeutics to Present New Preclinical Data for Selective SMARCA2 Inhibitor ... - Bluefield Daily Telegraph

Apr 09, 2026

Apr 09, 2026

New lung, breast and blood cancer data put Foghorn programs at AACR - Stock Titan

Apr 09, 2026

Apr 05, 2026

FHTX PE Ratio & Valuation, Is FHTX Overvalued - Intellectia AI

Apr 05, 2026

Apr 05, 2026

Foghorn Therapeutics Inc. (NASDAQ:FHTX) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat

Apr 05, 2026

Apr 02, 2026

FHTX Technical Analysis & Stock Price Forecast - Intellectia AI

Apr 02, 2026

Apr 02, 2026

FHTX Stock Price, Quote & Chart | FOGHORN THERAPEUTICS INC (NASDAQ:FHTX) - ChartMill

Apr 02, 2026

Apr 01, 2026

Strength Observed in Dianthus Therapeutics, Inc. (DNTH): Will Its 5.6% Increase Lead to Further Gains? - Bitget

Apr 01, 2026

Apr 01, 2026

Strength Seen in Dianthus Therapeutics, Inc. (DNTH): Can Its 5.6% Jump Turn into More Strength? - Yahoo! Finance Canada

Apr 01, 2026

Mar 31, 2026

FHTX Should I Buy - Intellectia AI

Mar 31, 2026

Mar 30, 2026

Aug Final Week: Can Foghorn Therapeutics Inc weather a recessionCPI Data & High Conviction Investment Ideas - baoquankhu1.vn

Mar 30, 2026

Mar 30, 2026

Setup Watch: Is Foghorn Therapeutics Inc part of any major index2026 Price Action Summary & Consistent Profit Trading Strategies - baoquankhu1.vn

Mar 30, 2026

Mar 29, 2026

Contrasting Foghorn Therapeutics (NASDAQ:FHTX) and Rocket Pharmaceuticals (NASDAQ:RCKT) - Defense World

Mar 29, 2026

Mar 28, 2026

Fundamentals Check: Is Foghorn Therapeutics Inc stock a good dividend stock2026 Earnings Impact & Daily Profit Focused Stock Screening - baoquankhu1.vn

Mar 28, 2026

Mar 20, 2026

Ideas Watch: Is Foghorn Therapeutics Inc stock a hidden gem2026 Fundamental Recap & Safe Entry Point Identification - baoquankhu1.vn

Mar 20, 2026

Mar 17, 2026

Citizens reiterates Foghorn Therapeutics stock rating on pipeline progress By Investing.com - Investing.com Canada

Mar 17, 2026

Mar 16, 2026

What is HC Wainwright's Forecast for FHTX FY2026 Earnings? - MarketBeat

Mar 16, 2026

Mar 15, 2026

Foghorn Therapeutics’ (FHTX) Outperform Rating Reiterated at Wedbush - Defense World

Mar 15, 2026

Mar 14, 2026

Foghorn Therapeutics (NASDAQ:FHTX) Downgraded to Hold Rating by Wall Street Zen - MarketBeat

Mar 14, 2026

Mar 14, 2026

FY2030 Earnings Estimate for FHTX Issued By HC Wainwright - Defense World

Mar 14, 2026

Mar 13, 2026

Brokers Offer Predictions for FHTX FY2030 Earnings - MarketBeat

Mar 13, 2026

Mar 13, 2026

Foghorn Therapeutics (FHTX) Receives a Buy from Guggenheim - The Globe and Mail

Mar 13, 2026

Mar 13, 2026

Analysts Offer Insights on Healthcare Companies: Tenax Therapeutics (TENX), RegenXBio (RGNX) and Foghorn Therapeutics (FHTX) - The Globe and Mail

Mar 13, 2026

Mar 12, 2026

Foghorn Therapeutics (FHTX) FY 2025 Losses Reinforce Bearish Unprofitability Narrative - simplywall.st

Mar 12, 2026

Mar 12, 2026

Jefferies reiterates Foghorn Therapeutics stock rating on pipeline data By Investing.com - Investing.com Australia

Mar 12, 2026

Mar 12, 2026

Jefferies reiterates Foghorn Therapeutics stock rating on pipeline data - Investing.com India

Mar 12, 2026

Mar 12, 2026

Foghorn Therapeutics reports $158.9M cash position, extends runway - Investing.com Australia

Mar 12, 2026

Mar 12, 2026

Foghorn Therapeutics (NASDAQ:FHTX) Earns "Outperform" Rating from Wedbush - MarketBeat

Mar 12, 2026

Mar 12, 2026

Stifel reiterates Foghorn Therapeutics stock rating at buy By Investing.com - Investing.com Australia

Mar 12, 2026

Mar 12, 2026

Stifel reiterates Foghorn Therapeutics stock rating at buy - Investing.com

Mar 12, 2026

Mar 12, 2026

Foghorn Therapeutics: Pioneering Precision Oncology with Chromatin Regulatory System Targeting and Gene Traffic Control Platform - Minichart

Mar 12, 2026

Mar 11, 2026

Foghorn Advances FHD-909 Trial and Strengthens Financial Position - TipRanks

Mar 11, 2026

Mar 11, 2026

Foghorn Therapeutics Provides Financial Update for 2025 and 2026 Strategic Outlook - Bitget

Mar 11, 2026

Mar 11, 2026

Foghorn Therapeutics Inc. (FHTX) Posts Fourth Quarter Loss, Surpasses Revenue Projections - Bitget

Mar 11, 2026

Mar 11, 2026

Foghorn Therapeutics Inc. (FHTX) Reports Q4 Loss, Beats Revenue Estimates - Yahoo Finance

Mar 11, 2026

Mar 11, 2026

Foghorn Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 11, 2026

Mar 11, 2026

Foghorn Therapeutics 10-K: $30.9M revenue, $(1.18) EPS - TradingView

Mar 11, 2026

Mar 11, 2026

Foghorn Therapeutics (NASDAQ:FHTX) Issues Quarterly Earnings Results, Misses Expectations By $0.04 EPS - MarketBeat

Mar 11, 2026